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ABSTRACT: A combined biochemical, structural, and cell
biology characterization of dictyostatin is described, which
enables an improved understanding of the structural
determinants responsible for the high-aﬃnity binding of this
anticancer agent to the taxane site in microtubules (MTs). The
study reveals that this macrolide is highly optimized for MT
binding and that only a few of the structural modiﬁcations
featured in a library of synthetic analogues resulted in small
gains in binding aﬃnity. The high eﬃciency of the dictyostatin
chemotype in overcoming various kinds of clinically relevant
resistance mechanisms highlights its potential for therapeutic
development for the treatment of drug-resistant tumors. A
structural explanation is advanced to account for the synergy
observed between dictyostatin and taxanes on the basis of their diﬀerential eﬀects on the MT lattice. The X-ray crystal structure
of a tubulin−dictyostatin complex and additional molecular modeling have allowed the rationalization of the structure−activity
relationships for a set of synthetic dictyostatin analogues, including the highly active hybrid 12 with discodermolide. Altogether,
the work reported here is anticipated to facilitate the improved design and synthesis of more eﬃcacious dictyostatin analogues
and hybrids with other MT-stabilizing agents.
■ INTRODUCTION
Microtubule-stabilizing agents (MSAs) are an important class of
clinically used anticancer drugs that target tubulin, the main
component of the microtubule (MT) cytoskeleton that is
responsible for the segregation of chromosomes during cell
division, among other functions. MSAs inhibit cell division by
virtue of their preferential binding to assembled MTs relative to
unassembled αβ-tubulin heterodimers.1 Although the proto-
typical paclitaxel and docetaxel have demonstrated great eﬃcacy
in inhibiting the growth of solid tumors, solubility problems and
development of resistance have stimulated the search for other
chemotypes with similar modes of action but improved
pharmacological proﬁles. The main mechanisms of resistance
to MSAs are (i) overexpression of βIII-tubulin isotypes and/or
membrane eﬄux transporters from the ATP-binding cassette
(ABC) superfamily, for example, P-glycoprotein (P-gp), which is
primarily responsible for the multidrug resistance (MDR)
phenotype and (ii) mutations in the β-tubulin gene.
This ongoing quest to identify new chemotypes acting as
MSAs has resulted in the discovery of several other important
antimitotic natural products (e.g., epothilones, sarcodictyins,
cyclostreptin, peloruside, laulimalide, zampanolide, dictyostatin,
and discodermolide) targeting at least three diﬀerent binding
sites2 on β-tubulin but displaying similar biological activities. Of
these, the dictyostatin and discodermolide chemotypes, which
are complex marine sponge-derived polyketides, show the
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highest aﬃnity for MTs3 and have enhanced water solubility.
These two properties apparently make these MSAs more prone
to circumventing P-gp-mediated MDR because their high
aﬃnities for an abundant protein should result in low
intracellular concentrations of the free drug and decreased
interaction with the eﬄux transporter.
We have previously shown that it is possible to structurally
optimize an MSA by studying the inﬂuence of selected chemical
modiﬁcations in critical pharmacophore regions and by
combining into a single molecular entity those changes that
result in favorable contributions to the binding free energy. This
rational approach has been successfully used to optimize the
binding to theMTs of several epothilone4 and taxane analogues.5
Figure 1. Chemical structures of the compounds used in this study.
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Interest in the dictyostatin chemotype6 has driven the
chemical synthesis of a variety of analogues to probe the
structural determinants of tubulin binding aﬃnity, ability to act as
an MSA, and cytotoxic activity.7,8 We have used a library of 16
structurally diverse compounds (Figure 1) arising from this
synthetic eﬀort to investigate the following: (1) the inﬂuence of
selected chemical modiﬁcations on the tubulin binding
constants, stoichiometry, and MT structural properties using
several biochemical and biophysical methods; (2) the binding
epitopes and bioactive conformations of these compounds by
means of X-ray crystallography and molecular modeling
techniques; and (3) their biological eﬀects on a representative
panel of tumor cell lines that are either sensitive or resistant to
other MSAs. As a long-term objective, this uniﬁed approach may
lead to the rational design of anticancer drug candidates with
signiﬁcantly increased cytotoxicity and reduced resistance
relative to the parent natural product.
In the present study, the structural modiﬁcations encompass a
large part of the dictyostatin (1, Figure 1) scaﬀold, along with
designed hybrids with discodermolide (3).9−14 Although some
limited information about the cytotoxicity of these compounds in
selected cancer cell lines has already been reported, little is
known about the details of their interactions with MTs and
tubulin, the contribution of the structural modiﬁcations to
complex formation, and the adoption of the bioactive
conformation.
Extensive nuclear magnetic resonance (NMR) studies have
been performed to propose a bioactive conformation for
dictyostatin and guide the synthesis of new and simpliﬁed
analogues (reviewed by Larsen et al.8). However, a crystal
structure of dictyostatin, either alone or in complex with tubulin,
was not previously available to enable the rational structure-
based design of improved analogues. To address this deﬁciency
and help elucidate the pharmacophore region of this important
MSA, we solved the structure of the resultant T2R-TTL−
dictyostatin complex at 2.3 Å resolution using X-ray crystallog-
raphy. We then simulated a macromolecular ensemble,
incorporating this experimentally determined protein−ligand
complex in the context of a reduced representation of a MT,
using molecular dynamics (MD). In silico evaluation of the
modeled complexes with the available synthetic dictyostatin
analogues was then used to rationalize the structure−activity
relationships (SARs). Taken together, these new results clarify
the long-standing issue of deﬁning the pharmacophore for the
dictyostatin chemotype and shed additional light on longitudinal
and lateral interactions inMSA-bound tubulin. They also provide
a powerful tool for the rational design of simpliﬁed dictyostatin
analogues and hybrids, including linker-modiﬁed targeted
versions for incorporation as payloads in antibody−drug
conjugates.
■ RESULTS
Cytotoxicity of Dictyostatin and Analogues in Resist-
ant Cells and Synergy with Paclitaxel and Peloruside A.
To initially explore the therapeutic potential of the dictyostatin
chemotype as an anticancer drug candidate, the cytotoxicities of
the compounds in Figure 1 were measured in a panel of cancer
cell lines that are resistant to other MSAs through three diﬀerent
mechanisms. The synergistic eﬀect of their combination with
either paclitaxel or peloruside A was also evaluated.
In the A2780, A2780AD, and A549 cell lines, all compounds
that were examined arrested the cell cycle in the G2/M phase, as
expected (Figure S1). In this regard, all of them, with the
exception of analogues 2 and 7, were also shown to enhance
tubulin polymerization in vitro in the absence of MT-associated
proteins (MAPS) and to reduce the critical concentration (Cr) of
tubulin required for assembly from 3.3 ± 0.1 μM in the absence
of drug to 0.4 ± 0.1 μM in the presence of parent dictyostatin
(Table 1).
The compounds were evaluated in A2780 ovarian tumor cells
and their resistant A2780AD counterparts (Table 1). As
previously shown,15 dictyostatin is active in this P-gp-over-
expressing resistant cell line. All of the compounds tested,
including those incorporating hydrophobic side chains, were
found to be able to overcome P-gp-mediated resistance. The
ﬁnding that all of the compounds show resistance indices
Table 1. Cytotoxicity of the Compounds (Chemical Structures in Figure 1) inOvarian Tumor Cell Lines Sensitive toMSA (A2780)
and MSA-Resistant due to P-gp Overexpression (A2780AD) and in Cervical Tumor Cell Lines Sensitive to MSA (HeLa S3) and
MSA-Resistant due to βIII-Tubulin Overexpression (HeLa-βIII)
compound A2780 (nM) A2780AD (nM) R/S HeLa-S3 (nM) HeLa βIII (nM) R/S Cr
b (μM)
dimethyl sulfoxide (DMSO, vehicle) 3.3 ± 0.1a
paclitaxel 1.8 ± 0.4 1491 ± 284 828.2 0.8 ± 0.2 8.6 ± 1.4 10.8 0.5 ± 0.1a
dictyostatin 2.55 ± 1 3.9 ± 0.2 1.5 1.5 ± 0.3 4.4 ± 0.8 2.9 0.4 ± 0.1
2 1203 ± 52 1423 ± 39 1.2 1050 ± 145 1160 ± 115.2 1.1 3.3 ± 0.3
discodermolide 28 ± 3 37.9 ± 5.2 1.35 6 ± 0.8 13.2 ± 1.25 2.2 0.6 ± 0.1
4 3.6 ± 1.5 5.1 ± 0.85 1.4 3.5 ± 0.7 10.2 ± 1.5 3.0 1.2 ± 0.1
5 5.5 ± 1.2 4.7 ± 1.6 0.85 9.7 ± 1.9 35 ± 2 3.6 1.4 ± 0.1
6 33.3 ± 11.6 16 ± 0.7 0.5 13 ± 3 18.5 ± 1.1 1.4 2.2 ± 0.2
7 7000 ± 300 8575 ± 125 1.2 2627.5 ± 182 7275 ± 625 2.8 3.4 ± 0.2
8 30.6 ± 8.2 17.6 ± 0.45 0.6 16.7 ± 3.2 15.3 ± 1.4 0.9 2.4 ± 0.1
9 4.9 ± 0.8 6.9 ± 0.4 1.4 1.9 ± 0.1 6.15 ± 0.8 3.2 0.5 ± 0.1
10 42.95 ± 4.7 94.4 ± 2.7 2.2 18.3 ± 1.9 21 ± 1.5 1.2 1.4 ± 0.2
11 66.6 ± 8.9 260 ± 43 3.9 25.85 ± 1.3 31.35 ± 4 1.2 0.8 ± 0.1
12 1.9 ± 0.9 0.9 ± 0.1 0.5 0.5 ± 0.02 1.8 ± 0.2 3.6 1.1 ± 0.1
13 69 ± 1.7 413.5 ± 21.6 6 32.6 ± 4.65 31.2 ± 6.5 1.0 1.2 ± 0.1
14 101.5 ± 3.95 89.3 ± 3.9 0.9 34 ± 3 67 ± 5.4 1.9 1.5 ± 0.2
15 488 ± 35 551.5 ± 53.3 1.1 719 ± 39 1047.5 ± 120 1.5 0.9 ± 0.1
16 2933 ± 219 4733 ± 437 1.6 2360 ± 133 1450 ± 104.1 0.6 1.8 ± 0.1
aData taken from ref 3. bCr for tubulin assembly in the GAB buﬀer.
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between 0.5 and 3.9 (for 11) indicates that they are not substrates
for this membrane drug eﬄux pump. Evaluation against HeLa-S3
andHeLa-βIII cervical tumor cells, the latter resistant to paclitaxel
through overexpression of the βIII isotype of tubulin, also showed
that all of the compounds in the library were equally active
against these two cell lines (Table 1).
Finally, the compounds were assayed in paclitaxel-resistant
PTX-10 and PTX-22 ovarian cancer cells harboring β-tubulin
variants F272V and A366T, respectively, and epothilone-
resistant A8 cells containing the β-tubulin variant T276I
(Table S1). Most of the compounds were not aﬀected by the
F272V mutation, as shown by much lower R/S indices than that
of paclitaxel (R/S = 37), although high values were obtained for
5, 8, 10, 11, 13, and 14. By contrast, only 11 and 14 showed R/S
indices 3 times lower than that of paclitaxel in cells expressing
A366T β-tubulin. Furthermore, A8 cells harboring T276I β-
tubulin did not show resistance to any of the compounds tested.
As anticipated from earlier work,12 the synthetic hybrid 12 of
dictyostatin with discodermolide was generally more potent (low
or sub-nanomolar) in the cell lines tested than either natural
product itself.
Previous studies had indicated that although discodermolide
and paclitaxel share the same binding site on β-tubulin, their
combination is synergistic in tumor cell lines16−18 and in
xenograft tumor-implanted animals.19 All of the compounds
tested, with the exception of 10, were shown to act synergistically
with paclitaxel (Table S2), as previously observed for
discodermolide16,17,20 and two other analogues.18 Signiﬁcantly,
when peloruside A, an MSA targeting a diﬀerent binding site on
β-tubulin,21 was used in the same cell line in place of paclitaxel,
the synergy was only observed at low ligand concentrations, and
none was observed with 12 (Table S2).
Morphological Eﬀects of the Compounds on the Cell
Cytoskeleton. The eﬀect of the compounds on the cell
cytoskeleton was evaluated in human lung carcinoma A549 cells
at diﬀerent ligand concentrations (Figure 2). The immuno-
ﬂuorescence experiments show that the analogues potently
induce the emergence of abnormal MT bundles, as for the parent
Figure 2. Eﬀect of the compounds on theMT network and the nuclear morphology of A549 cells. Eﬀect of dictyostatin analogues 4, 5, 6, 8, 9, 10, and 11
and hybrid molecules 12, 13, 14, and 15 on the MT network, the mitotic spindle, and the nuclear morphology of A549 cells in comparison with
untreated cells (DMSO), cells treated with paclitaxel, and the reference parent compounds dictyostatin and discodermolide. Cells were incubated for 24
h in the presence of DMSO (A, A′), paclitaxel 100 nM (B, B′), dictyostatin 50 nM (C, C′), discodermolide 100 nM (D, D′), 4 250 nM (E, E′), 5 200 nM
(F, F′), 6 100 nM (G, G′), 8 200 nM (H, H′), 9 100 nM (I, I′), 10 800 nM (J, J′), 11 2 μM (K, K′), 12 60 nM (L, L′), 13 1.8 μM (M, M′), 14 6 μM (N,
N′), and 15 8 μM(O,O′). MTs (A, B, C, D, E, F, G, H, I, J, K, L, M, N, andO) are labeled with the DM1A antibody against α-tubulin, whereas DNA (A′,
B′, C′, D′, E′, F′, G′, H′, I′, J′, K′, L′, M′, N′, andO′) is marked withHoechst 33342. The insets (A, A′, B, B′, C, C′, the latest representative for all ligands
examined) show the mitotic spindles in the same preparations. The bar at O′ represents 10 μm, with all panels showing the same magniﬁcation.
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compounds dictyostatin and discodermolide, and also for
paclitaxel, but with some diﬀerences in the morphology. In the
case of taxanes, the bundles are long and thin, whereas in the case
of the compounds tested here, they are shorter and thicker.
Nonetheless, all compounds induced a somewhat parallel
alignment of MTs (straighter MTs) in the absence of MT
bundles, in contrast to the organized MT network that was
observed in the untreated (DMSO) cells. Dictyostatin and 12
were especially potent in inducing MT bundles, already apparent
at concentrations of∼50 nM, as well as discodermolide, 6, and 9,
for which this eﬀect was visible at concentrations similar to those
of paclitaxel (100 nM). Compounds 4, 5, and 8 required
concentrations of ∼250 nM, whereas the other compounds
assayed (e.g., 11, 13, 14, and 15) were signiﬁcantly less active,
requiring μM concentrations to induce the MT bundles.
Another morphological diﬀerence observed was the presence
of a large number of micronucleated cells, multipolar mitotic
spindles, and multiple asters (Figure 2).
Aﬃnity of the Compounds for the Taxane-Binding
Site. The binding of the compounds to the paclitaxel site in the
MTs was tested using the displacement of the bona ﬁde
ﬂuorescent paclitaxel analogue Flutax-24,5 (Table 2). Because 4,
6, 9, and 12 completely displaced Flutax-2 at equimolar
concentrations, we also carried out a direct competition
experiment with epothilone B (binding aﬃnity = 7.5 × 108
M−1 at 35 °C) (Table 2) to measure their high binding aﬃnities
more accurately.22
Eﬀects of the Compounds on the MT Structure. The
eﬀect of the compounds on the MT structure was studied using
small-angle X-ray scattering (SAXS), which allows the measure-
ment of the average number of protoﬁlaments of the induced
MTs, as determined by the lateral contacts between adjacent
tubulin dimers.23 The largest eﬀect was exerted by dictyostatin
and discodermolide, which induced 14.5 ± 0.3 protoﬁlament
MTs, whereas the number of protoﬁlaments in the presence of
analogues 5, 6, and 11 (13.7 ± 0.1, 13.5 ± 0.3, and 13.2 ± 0.5,
respectively) was similar to that observed in the absence of drug
(13.6 protoﬁlaments).24 This number was even smaller in the
presence of dictyostatin−discodermolide hybrids 12, 14, and 15
(13.2 ± 1, 13.1 ± 0.2, and 12.9 ± 0.3, respectively).
Crystal Structure of the T2R-TTL−Dictyostatin Com-
plex. The X-ray crystal structure of the dictyostatin-bound
tubulin was determined to 2.3 Å resolution and is shown in
Figure 3. As expected, dictyostatin occupies the taxane-binding
site on β-tubulin, and in agreement with previous proposals,25,26
its C19-hydroxyl forms two hydrogen bonds with both the main
chain carbonyl of Pro274 and the main chain amide of Thr276.
This central anchoring point is equivalent to that of the oxetane
oxygen in paclitaxel27 and that of the carbonyl C1−O in
epothilone A.28 Two additional hydrogen bonds are formed by
the hydroxyls at C7 and C13 in dictyostatin to the side chains of
His229 and Asp226, respectively. The interaction at C13 of
dictyostatin is equivalent to the C7−OH−Asp226 interaction
observed in the tubulin−epothilone A complex.28 The methyl
substituent of the Thr276 side chain is in hydrophobic contact
with the C22 methyl group of dictyostatin, whereas the hydroxyl
substituent on the amino acid residue is not involved in the
recognition of the ligand. This observation satisfactorily accounts
for the resilience of dictyostatin to the T276I mutation, which
severely compromises binding of the epothilone chemotype.
Furthermore, the oleﬁns at C3 and C25 form two weak CO···
HC hydrogen bonds30 to the main chain carbonyls of Gly370
and Thr276, respectively. The dictyostatin−tubulin binding
arrangement is completed by a cation−π interaction between the
oleﬁnic C23−C26 moiety and the guanidinium of Arg278 in the
M-loop, and by van der Waals and hydrophobic interactions with
Leu217, Leu230, Ala233, Phe272, Leu275, and Leu371 (Figure
3A,B), distinct from most of the epothilone contacts (Figure
3C). Notably, the F272V replacement does not aﬀect the binding
Figure 3. Structure of the tubulin−dictyostatin complex. (A) Close-up
view of the tubulin−dictyostatin complex. Dictyostatin is shown as a
yellow stick representation. β-Tubulin is displayed as a light gray ribbon.
Key residues forming the interaction with the ligand are shown as a stick
representation and are labeled. Hydrogen bonds are highlighted as
dashed black lines. (B) Schematic 2D representation of the interactions
responsible for the aﬃnity of dictyostatin for the taxane-binding site in
β-tubulin. Green rectangles represent hydrophobic contacts. Standard
and CO···HC hydrogen bonds are shown as thick and thin dotted
lines, respectively. Average interaction energies (kJ mol−1), as calculated
from theMD simulations,29 are given for the most important interacting
β-tubulin residues. (C) Superimposition of the tubulin−dictyostatin
(yellow sticks, light gray ribbon) and tubulin−epothilone A (violet-
purple sticks and ribbon) structures. Hydrogen bonds of the tubulin−
dictyostatin complex are highlighted as dashed black lines.
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aﬃnity of dictyostatin, although it has a strongly deleterious
eﬀect for some of its analogues, for example, 5, 8, 10, 11, 13, 14,
and 16 (Table 2).
Arguably, the most novel and striking feature of the T2R-
TTL−dictyostatin complex reported here is the presence of two
(CH···O) hydrogen bonds involving the oleﬁnic carbons at
C3 and C25 and the carbonyl oxygens of Gly370 and Thr276,
respectively. This type of interaction is considered weaker in
energy30 than the other hydrogen bonds described above but
nonetheless appears to be signiﬁcant for proper ligand
orientation and stabilization within the binding site.
The tubulin-bound conformation of dictyostatin in this
complex is remarkably similar to both the solid state (deposited
in the Cambridge Structural Database with code Vintan0131) and
solution32 structures of its closest MSA relative, discodermolide.
Furthermore, this same conformation is also observed in an
independently solved structure of discodermolide bound to the
T2R-TTL complex (Figure S2). This is particularly noteworthy
in view of the ∼30 times greater binding aﬃnity of
discodermolide for this β-tubulin site compared with that of its
22-membered macrolide relative, dictyostatin3 and the fact that
the entropic contribution to binding is more favorable for
discodermolide, which argues against a loss of conformational
freedom for this compound upon binding.
Simulation of Dictyostatin Binding to a Reduced
Representation of an MT. The importance of studying the
binding of an MSA in the context of a realistic representation of
an MT33 led us to expand the size of our previous tubulin model
system beyond that of a simple dimer.34 A short MT stretch was
built by taking two α1-β1-α2 segments from two vicinal
protoﬁlaments33 and incorporating one bound drug molecule
(either dictyostatin or epothilone A were used here for
comparative purposes) into each central β-tubulin subunit28
(see Experimental Procedures). The conformational stability of
each of these assemblies, in which both M-loops are structurally
ordered as α-helices at the beginning, was then examined by
means of unrestrained MD simulations in an explicit aqueous
solvent. By using this computational protocol, two distinct MSA-
binding sites could be monitored in parallel: site 1, at the
interface between two neighboring protoﬁlaments and site 2,
devoid of any protein lateral contacts but exposed to the bulk
solvent (Figure S3). Because no major diﬀerences are found in
the binding site between the straight and curved conformation,28
the large diﬀerences in the binding aﬃnity that are consistently
Figure 4.Model of dictyostatin bound to a MT. (A) Superimposition of a representative structure of each major cluster of dictyostatin conformers (C
atoms colored in orange) bound to β-tubulin in subunit B (C atoms colored in blue, site 1) and F (C atoms colored in yellow, site 2) along the MD
simulation (100 ns) onto subunit B of the crystal structure of the dimeric tubulin in the complex with dictyostatin (C atoms colored in gray) reported in
this work. (B) Time evolution of distances (Å) relevant to the pharmacophore along the MD simulation in the sites of B and F tubulin monomers.
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observed experimentally between the unassembled and
assembled tubulin must reﬂect the relevance of the lateral
contacts for the binding.
When the T2R-TTL−dictyostatin complex was simulated in
the context of our reduced representation of a MT, the hydrogen
bonds initially present between OG1(Thr276) and both
NE2(Gln281) and NH1(Arg284) could not be stabilized by
the bound ligand (Figure 4), unlike the situation observed in the
epothilone A complex28,34 and (Figure S4). This is a direct
consequence of the lack of pharmacophore interactions in
dictyostatin equivalent to those involving the side-chain thiazole
ring nitrogen and the C3−OH group attached to the macrocycle
in epothilone A (Figure 3C). Instead, transient hydrogen bonds
were observed between NE2(Gln281) and the lactone carbonyl
oxygen of dictyostatin and also between NH1(Arg284) and the
Asp90 carboxylate of the neighboring β1 subunit (Figure 4). The
weak O(Thr276)−C25 hydrogen bond was the most aﬀected in
the absence of neighboring protoﬁlaments (site 2). By contrast,
the hydrogen bond between OD1/OD2(Asp226) and OH at
C13 was reinforced in both sites for the full duration of the
simulation and that established between NE2(His229) and the
hydroxyl at C7 was maintained during most of the simulated
trajectory. The structural rearrangements of the M-loops were
more noticeable in the tubulin complex with dictyostatin relative
to that with epothilone A, and also in site 2 relative to site 1, as
expected from the larger solvent exposure of the former.
■ DISCUSSION
In 2001, discodermolide entered phase I clinical trials as an
anticancer drug candidate, with Novartis.35 However, it did not
advance into phase II because of unexpected lung toxicity.36 Until
now, no other MSA belonging to either the discodermolide or
dictyostatin chemotypes has entered clinical trials despite the
high aﬃnity of these compounds for tubulin,3 as well as their
potent cytotoxicity and ability to overcome P-gp-mediated
MDR.5 Nevertheless, these promising biological attributes have
inspired us to further study the dictyostatin chemotype to
identify the structural determinants responsible for their high
binding aﬃnities and their potent eﬀects in inhibiting the growth
of tumor cells.
SARs for the Dictyostatin Analogues.Out of all analogues
of dictyostatin that we examined (the open-chain discodermolide
notwithstanding), only 4, 6, 9, and 12 showed a greater aﬃnity
for tubulin than the parent compound (Table 2) indicating that,
in contrast to paclitaxel and epothilones,4,5 dictyostatin is highly
optimized for binding toMTs, and there is scope to prepare even
more eﬃcacious analogues based on the further evolution and
optimization of this novel macrocyclic scaﬀold.
Ourmodeling studies provide a rationale for these ﬁndings and
for some earlier SAR results.37 Thus, the dramatic loss of aﬃnity
found for the ring-contracted analogue 2 and similar 20-
membered macrolides resulting from C21 to C19 trans-
lactonization14 is a direct consequence of the pronounced
conformational changes relative to that in dictyostatin (Figure
5A) to the extent that the pharmacophore hotspots essential for a
strong tubulin binding are missing altogether. Removal of the
methyl group at C6, as in analogue 4,14 is likely to introduce some
additional conformational ﬂexibility in the macrocycle, leading to
an improved interaction between the C1−C5 conjugated
dienoate system and the Gly370 backbone, which is reﬂected
in a gain in the free energy of binding of −2.7 kJ mol−1. By
contrast, removal of the methyl group at C16, as in analogue 10,
results in a weaker binding (ΔΔG +9.1 kJ mol−1), most likely due
to the loss of favorable interactions with the hydrophobic pocket
formed by the side chains of Leu230, Ala233, Phe272, and
Leu275, as anticipated from the previous modeling work.38
Replacement of the hydroxyl group at C9 with a methoxy group
(as found in the highest-aﬃnity compound 9) probably shields
the hydrogen bond between OH at C7 of dictyostatin and
NE2(His229) from disrupting the interactions with water
molecules (ΔΔG −4.6 kJ mol−1). However, epimerization at
C9,15 as featured in both 7 and 11, disturbs the interaction
involving OH at C7 and promotes conformational changes in the
macrocycle that preclude an optimum ﬁt into the binding site and
translate into considerable losses of aﬃnity (ΔΔG +5.3 and
+10.8 kJ mol−1). Selective hydrogenation of the C2−C3 double
bond in 6 slightly increases the binding aﬃnity (ΔΔG −1.4 kJ
mol−1), whereas hydrogenation of both C2−C3 and C4−C5
double bonds in 814 increases the ﬂexibility of themacrocycle and
leads to a lower aﬃnity for tubulin (ΔΔG +6.1 kJ mol−1). By
contrast, introduction of a trisubstituted double bond at C15−
C16, together with additional methylation at C18 so as to
incorporate some of the structural features present in
discodermolide,39 yields the most cytotoxic hybrid compound
12, which possibly owes its higher aﬃnity to increased van der
Waals interactions with the side chains of Leu217 and Leu230.
Nevertheless, other hybrids such as 13, 14, and 16, or more
sophisticated constructs merging features from dictyostatin,
discodermolide, and taxanes, such as 14 and 17, have
considerably less aﬃnity than the parent compound, essentially
because the extra substituents are not properly oriented to
improve the ﬁt into the taxane-binding site of β-tubulin (Figure
5B).
Furthermore, this bound conformation also accounts for SAR
results recently reported for some other active dictyostatin
analogues40 designed as putative payloads for antibody−drug
conjugates. By inspection of the tubulin-bound conformation, it
is apparent that the C6 methyl group of dictyostatin is located
deep in the binding pocket, such that a functionalized alkyl linker
placed at this position will extend toward H1 or point inside of
the binding pocket and occupy the space that is otherwise ﬁlled
by the C13 side chain of paclitaxel (Figure S5A,B). By contrast,
inclusion of a functionalized alkyl linker in place of the C12
Figure 5. Comparison between the predicted structures of the
analogues. (A) Superimposition of a representative structure of the
major conformer of isodictyostatin (2, C atoms colored in gray), as
simulated using MD for 100 ns in a box of TIP3P water molecules, onto
the crystal structure conformation of dictyostatin (dictyostatin, C atoms
colored in orange). (B) Molecular model showing the best docking
poses of compounds 4−16 bound to the taxane-binding site of β-
tubulin. The very weak binder isodictyostatin (2) and hybrid 14, which
incorporates a fragment derived from docetaxel, are not shown.
ACS Omega Article
DOI: 10.1021/acsomega.6b00317
ACS Omega 2016, 1, 1192−1204
1199
methyl group will cause full exposure of this group to the solvent,
and the ﬂexible linker may perturb the interaction of the ligand by
interfering with the elements surrounding the binding site
(Figure S5C).
Comparison of Epothilone A and Dictyostatin Chemo-
types.When the β1 subunits of [epothilone A:(α1-β1-α2)]2 and
[dictyostatin:(α1-β1-α2)]2 complexes were best-ﬁt superimposed
(Figure S6), these two MSAs were revealed to share only two
anchoring points that involved hydrogen bonds (Table S3),
namely, the carboxylate of Asp226 (OH at C3 of epothilone A vs
OH at C13 of dictyostatin) and the backbone amide nitrogen of
Thr276 (O1 of epothilone A vs OH at C19 of dictyostatin).
Notably, only the latter interaction is shared with paclitaxel (PDB
entry 1JFF),27 the prototypical MSA that engages its oxetane
oxygen in a hydrogen bond. In the case of dictyostatin, the
strength of this anchoring point is augmented because the OH
group at C19 simultaneously donates a hydrogen bond to
O(Pro274). This common polar pharmacophore is comple-
mented by distinct van der Waals interactions involving the side
chains of His229 and a number of hydrophobic residues (Figure
3B).
A unique structural feature of dictyostatin relative to other
MSAs is the presence of two conjugated diene regions that give
rise to two weak CO···HC hydrogen bonds30 involving the
oleﬁnic carbons at C3 and C25 on the one side and the backbone
carbonyl groups of Gly370 and Thr276 on the other side (Figure
3B). These distinctive interactions are maintained throughout
the MD simulations. In addition, the alkene at C2−C3 in
dictyostatin interacts with the hydrophobic side chain of Leu371,
whereas the C22−C26 conjugated diene system can establish a
stabilizing π−cation interaction with the guanidinium group of
Arg278.
In summary, dictyostatin makes use of some common binding
hotspots on the tubulin protein employed by epothilone A
(Asp226, His229, Phe272, Thr276, and Arg278) in a way that is
compatible with maintaining an α-helical conformation of theM-
loop, even though this is not present in the crystal structure.
Nonetheless, the Thr276 and Gln281 side chains of this
structural element are found to be more disordered because of
the lack of highly directional hydrogen-bonding interactions with
the bound ligand.
Compounds of the Dictyostatin Chemotype are
Eﬀective in All Types of Taxane-Resistant Cells. From a
potential therapeutic standpoint, another remarkable property of
the synthetic analogues based on the dictyostatin chemotype is
their pronounced ability to overcome all kinds of known
resistance mechanisms related to tubulin-targeting anticancer
drugs (i.e., P-gp overexpression, mutations in their binding site,
and expression of the βIII tubulin isotype).
Signiﬁcantly, the dictyostatin chemotype shows potent (low
nanomolar) activity (Table 1) against P-gp-overexpressing
resistant cells (A2780AD), independent of the binding aﬃnity.
This eﬀect is probably not related to the competition between
the target and the drug eﬄux pump, as is the case for other high-
aﬃnity tubulin modulators,5,41 but is likely due to a low aﬃnity
for the pump, which prefers compounds with high lipophilicity
(e.g., uncharged and possessing aromatic rings).42
With respect to the resistant cell lines harboring mutations, the
relative eﬃcacy depends on the compound tested (Table S1).
Although most of the analogues tested are not aﬀected by the
F272V mutation, as shown by R/S indices much lower than that
for paclitaxel (R/S = 37), the high values obtained for a few of
them, namely, 5, 8, 10, 11, 13, and 14, suggest that intraprotein
or ligand−protein interactions involving this aromatic residue are
highly sensitive to relatively subtle conformational changes in the
macrocycle and/or particular variations in the side chain
replacement. By contrast, the ﬁnding that only 11 and 14 show
R/S indices around 4.0 (i.e., three times lower than that of
paclitaxel) in cells expressing the A366T β-tubulin variant
indicates a much smaller inﬂuence of this residue on the binding
of this chemotype, which is in agreement with the present
modeling studies. Likewise, the observation that A8 cells
harboring T276I β-tubulin do not show resistance to any of
the compounds tested concurs with the lack of direct interactions
of dictyostatin and its analogues with the side chain hydroxyl of
this amino acid residue, as was also found for paclitaxel. Finally,
the ﬁnding that the side chain of Ser277 in the tubulin/
dictyostatin complexes is directed away from the bound ligand
(as is the case for the tubulin/epothilone complexes28)
satisfactorily accounts for the fact that the resistant cells
overexpressing the βIII isotype are equally sensitive to these
MSA chemotypes.43
Synergy between Paclitaxel and Dictyostatin Chemo-
types. The results obtained in this study (Table S2) are in
accordance with the previous observation that although
discodermolide and paclitaxel share the same tubulin-binding
site, their combination is synergistic in both tumor cell
cultures16−18 and tumor-implanted animals.19
Such a synergy has also been described between paclitaxel and
laulimalide or peloruside A,44−46 which are MSAs targeting a
diﬀerent binding site. A crosstalk between the laulimalide/
peloruside and taxane sites via the M-loop of β-tubulin has been
advanced as an explanation for this synergy, which is based on
comparing the conformation of the Gln294−Phe296 segment in
the presence and absence of bound drugs because it adopts a
helical, polymerization-competent, MT-stabilizing “on-state” or
a turn-type III, “oﬀ-state”.21 However, this kind of mechanism
would not be possible for compounds that share a common
binding site.
However, this mechanism implies that a single tubulin
molecule should be ligated by both ligands to experience this
synergy, and this is not the case. It is important to realize that
both the synergies between paclitaxel and dictyostatin and
between paclitaxel-site and laulimalide-site ligands in the
inhibition of cell proliferation occur at low nanomolar drug
concentrations, far below those needed to bind tubulin
stoichiometrically within the cell. At such low nanomolar IC50
values, the percentage of tubulin bound by either a paclitaxel-site
or a laulimalide-site ligand is in the range of 2−5% of all of the
available proteins.5 Considering that binding to the paclitaxel and
the laulimalide sites is independent (binding of laulimalide does
not signiﬁcantly modify the binding aﬃnity of the taxane-site
ligand47), these ﬁgures imply that the probability that a single
tubulin protein is bound by both taxane-site and laulimalide-site
ligands is between 0.04 and 0.25%. This makes it unlikely that an
individual tubulin protein has both taxane and laulimalide
molecules simultaneously bound to it. Thus, both in the taxane-
site/laulimalide site and in the dictyostatin and taxane chemo-
types, the observed synergy should be attributed to the
interdimer eﬀects caused by cooperativity of their diﬀerential
eﬀects when bound at diﬀerent tubulins of the sameMT lattice as
opposed to an intradimer eﬀect.
Eﬀects on the MT Structure. In contrast to what would be
expected from consideration of an earlier model for a binding
pose for discodermolide25 far from the M-loop, a signiﬁcant
eﬀect of both dictyostatin and discodermolide was observed here
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on the MT protoﬁlament number. Because these two MSAs
induce 14.5 ± 0.1 protoﬁlament MTs, they must exert a strong
inﬂuence on the interprotoﬁlament lateral interactions that
stabilize the MTs. Interestingly, this inﬂuence has the opposite
eﬀect to that resulting from paclitaxel binding, which reduces this
number.24 Reduction in the protoﬁlament number arises from a
smaller interprotoﬁlament angle and vice versa. The fact that
these two opposite eﬀects can take place in diﬀerent β-tubulin
subunits within the same MT provides a possible structural
explanation for the synergistic eﬀect observed.
Intriguingly, the number of protoﬁlaments does not change in
the MTs stabilized by epothilone A, an MSA for which the M-
loop appears structurally deﬁned as an α-helix in the X-ray
tubulin−ligand complexes.21,28 This M-loop conformation,
which is also observed in the complex with zampanolide,28
correlates with the conformation observed in the MTs,33 despite
the fact that the (α1-β1:α2-β2) tetramer in the T2R-TTL−ligand
complexes is bent and most of the M-loop is solvent exposed.
The interprotoﬁlament lateral interactions are present, however,
in our modeled [dictyostatin/(α1-β1-α2)]2 and [epothilone A/
(α1-β1-α2)]2 complexes, and some of the features observed can
be important to account for the stabilization of the lateral
contacts brought about by drug binding beyond the well-
established role of the side chain of Tyr283 in the M-loop:33 ﬁrst,
the stabilizing role of the water molecule that bridges a hydrogen-
bonding interaction between the main chain NH(Arg278) at the
plus end of the M-loop’s helical dipole and the backbone
O(Leu217); second, a hydrogen bond between O(Tyr283) at
the minus end of the M-loop helix and NH(Arg88) in the
neighboring β-tubulin subunit; third, another hydrogen bond
between O(Gln282) in the M-loop and NH(Ala57) in the 56−
59 twisted β-hairpin of the neighboring β-tubulin subunit; and
ﬁnally, NH of Arg284 at the minus end of the M-loop helix is
engaged in a hydrogen bond with O(Ser280) within the helix,
whereas its carbonyl oxygen is exposed to the solvent and its
guanidinium side chain is extended to allow the establishment of
multiple electrostatic interactions with the carboxamide oxygen
of Gln294, the hydroxyl of Thr276, and the carboxylate of
Glu290.
Altogether, we believe that the network of interactions just
described is sensitive to the presence of a bound ligand in the
taxane-binding site in such a way that the spatial relation between
the M-loop (R278GSQQY283) in one β-tubulin subunit and the
twisted β-hairpin (Y53NEAA̲G̲NKYV62) of the β-subunit in the
neighboring protoﬁlaments changes slightly but suﬃciently to
act as a wedge that can either increase or decrease the
interprotoﬁlament angle and thereby lead to MTs with a higher
or lower number of protoﬁlaments. An important exception is
epothilone A that binds to MTs without aﬀecting their overall
structure most likely because its rather unique set of interactions
gives rise to stabilization of the side chains of Thr276 and
Gln281. Additional work is in progress to provide further support
for this hypothesis.
■ EXPERIMENTAL PROCEDURES
Protein and Ligands. Puriﬁed calf-brain tubulin and
chemicals were obtained as previously described.48 Stabilized,
moderately cross-linked MTs were prepared as reported
earlier.49 The recombinant expression and puriﬁcation of the
stathmin-like domain of RB3 and chicken TTL in bacteria, and
the reconstitution of the T2R-TTL complex was performed as
described previously.28
Peloruside A was kindly provided by Dr. Peter T. Northcote
(Victoria University of Wellington), Flutax-2 was kindly
provided by Dr. Wei-Shuo Fang (Institute Materia Medica
Beijing), and epothilone B was kindly provided by Prof. Karl-
Heinz Altmann (ETH, Zürich). Paclitaxel was kindly provided by
the National Cancer Institute (Bethesda, USA).
Dictyostatin (1), isodictyostatin (2), discodermolide (3), 6-
desmethyldictyostatin (4), 10,11-dihydrodictyostatin (5), 2,3-
dihydrodictyostatin (6), 16-desmethyl-9-epi-dictyostatin (7),
2,3,4,5-tetrahydrodictyostatin (8), 9-methoxydictyostatin (9),
16-desmethyldictyostatin (10), 9-epi-dictyostatin (11), and the
discodermolide/dictyostatin hybrids (12−15) were synthesized
as previously described: dictyostatin,50 (2) (A. Meyer, Ph.D.
thesis, University of Cambridge, 2005), discodermolide,51 (4, 6,
8),14 (5),13 (7, 9, 10, 11),10 (12),12 (13),52 (14),53 and (15,
16).11
The ring-contracted analogue 2 was separated from residual
dictyostatin before each experiment using a depletion method. A
sample of 2 in the desired buﬀer was incubated for 30 min at 25
°C with a 5% molar ratio of stabilized MTs. The stabilized MTs
were then removed by pelleting in a TLA 100.2 rotor at 50 000
rpm for 20 min in an Optima TLX ultracentrifuge.
Biochemical Characterization. The binding constants of
the compounds to stabilized MTs were measured as previously
described.5 The Cr of the tubulin assembly in the presence of
compounds in the GAB buﬀer (3.4 M glycerol, 10 mM sodium
phosphate (NaPi), 1 mM EGTA, 6 mMMgCl2, and 1 mMGTP,
pH 6.7) was measured as reported earlier.3
Crystallization, Data Collection, and Structure Sol-
ution. Crystals of T2R-TTL were grown as previously
described,28,54 except that tubulin was not subjected to a cycle
of polymerization/depolymerization before complex assembly
and crystallization. Crystals were soaked overnight in a reservoir
solution (10% PEG 4K, 16% glycerol, 30 mM CaCl2, 30 mM
MgCl2, 0.1 M MES/imidazole pH 6.7, 1 mM AmPPcP, 10 mM
DTT, and 0.1 mM GDP) supplemented with 1 mM dictyostatin
and were collected directly from the drop and ﬂash-cooled in
liquid nitrogen. Data collection at beamline X06DA at the Swiss
Light Source (Paul Scherrer Institut, Villigen, Switzerland) and
data processing and structure solution were performed as
previously described.54 Details of the data collection and
reﬁnement statistics are given in Table S4.
The chains in the T2R-TTL−dictyostatin complex are deﬁned
as follows: chain A, α1-tubulin; chain B, β1-tubulin; chain C, α2-
tubulin; chain D, β2-tubulin; chain E, RB3; and chain F, TTL.
Chain D was used throughout for the structural analysis and
ﬁgure preparation. Structure visualization, molecular editing, and
ﬁgure preparation were performed with PyMOL (the PyMOL
molecular graphics system, version 1.5.0.5. Schrödinger, LLC).
The atomic coordinates and structure factors have been
deposited in the Protein Data Bank (www.rcsb.org) under
accession code 5MF4 (T2R-TTL−dictyostatin).
In Silico Model Building and Molecular Simulations.
Our reduced representation of an MT for simulation purposes
consisted of the subunits α1:β1:α2 from one protoﬁlament
together with the closely interacting α1′:β1′:α2′ subunits from a
neighboring protoﬁlament (Figure S3). Details of the con-
struction of the macromolecular ensemble are described in
Supporting Information.
X-Ray Scattering Measurements. Ligand-induced MTs in
the presence of the desired ligands were prepared and their SAXS
proﬁles were collected on a Bruker Nanostar system as
described.23
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Cell Biology. Cytotoxicity evaluation was performed on
A2780,55 P-gp-overexpressing A2780AD,56 1A9, PTX10,
PTX22, and A8 (A2780-derived)57 human ovarian carcinoma
cell lines, as well as HeLa and βIII-transfected HeLa cervical cell
lines58,59 using a modiﬁed MTT assay.60 Synergy between drugs
was evaluated using the combination index (CI), as previously
deﬁned,61,62 which indicates additivity, antagonism, and synergy
for values of 1, >1, and <1, respectively. Indirect immuno-
ﬂuorescence was performed in A549 cells, as previously
described.63 The cell cycle analysis was performed as previously
reported.3
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